News | February 22, 2007

Prominent Heart Failure Docs to Lead Heart Assist Device Trial

Feb. 23, 2007 — Dr. William T Abraham of Ohio State University, Columbus, Ohio and Dr. Patrick M McCarthy of Northwestern University, Chicago, Illinois, have agreed to become the Co-Principal Investigators for C-Pulse Feasibility Trial in the U.S. Australia-based Sunshine Heart, a global medical device company, says it is committed to the commercialization of the C-Pulse, an implantable, non-blood contacting, mechanical heart assist device for the treatment of people with heart failure.

The appointment continues Sunshine Heart's progress towards commencing the multicenter U.S. Feasibility Trial during 2007 following the positive meeting with the FDA that was announced on 22 December 2006.

William T Abraham, M.D. FACP, FACC, FAHA is Professor of Internal Medicine, Division Director of Cardiovascular Medicine and Deputy Director of the Davis Heart and Lung Research Institute at Ohio State University. He has participated in more than 100 drug and device clinical trials and has been International Principal or Co-Principal Investigator for several of Medtronic's heart failure pacemaker trials (Miracle, Miracle ICD).

"The C-Pulse has great potential in the treatment of patients with moderately severe heart failure," said Dr. Abraham.

Patrick M McCarthy, M.D. is the Heller-Sacks Professor of Surgery, Division Chief of Cardiothoracic Surgery and Co-Director of the Bluhm Cardiovascular Institute of the Northwestern University Feinberg School of Medicine. Dr. McCarthy has been recognized as an innovative and leading cardiovascular surgeon and researcher. He has been a clinical investigator in trials of several heart assist devices and is Chairman of the Society of Thoracic Surgeons/American Association for Thoracic Surgery Joint Working Group on New Technology.

Dr. McCarthy recently presented the C-Pulse(TM) at University's Heart Failure Summit, in "The Future of Congestive Heart Failure" Session.

The C-Pulse is an implantable, non-blood contacting mechanical heart assist device designed to provide long term support for people with moderate to severe (Class III) heart failure. The device is designed to be implanted without the need for bypass and does not contact the bloodstream, reducing the risk of bleeding and blood clot formation.

The C-Pulse Cuff consists of a wrap and a balloon which is placed around the aorta just above the heart. The balloon is inflated and deflated to the rhythm of the heart to improve blood supply to both the body and the heart muscle, while reducing the workload on the heart.

The C-Pulse Driver is an external wearable unit that is linked by an air tube to the cuff and detects the heart's natural rhythm and controls inflation and deflation of the balloon in rhythm with the heart.

Implantation of the C-Pulse involves wrapping the cuff around the aorta. No incisions into the aorta are needed so that the device never comes into contact with the patient's bloodstream. The C-Pulse(TM) balloon inside the cuff is designed to inflate in a way that rolls the wall of the aorta inward in a gentle 'thumb printing' manner. The balloon is inflated and deflated rhythmically to improve blood supply to the heart and body as well as reduce the workload of the heart.

For further information visit www.sunshineheart.com


Related Content

News | Ventricular Assist Devices (VAD)

June 19, 2024 — When electrophysiologist Eugenio Cingolani, MD, isn’t seeing patients, he can usually be found in his ...

Home June 19, 2024
Home
News | Ventricular Assist Devices (VAD)

October 31, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

Home October 31, 2023
Home
News | Ventricular Assist Devices (VAD)

June 7, 2023 — Magenta Medical Ltd. has announced the initiation of its FDA-approved Early Feasibility Study with the ...

Home June 07, 2023
Home
News | Ventricular Assist Devices (VAD)

March 1, 2023 — Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Home March 01, 2023
Home
News | Ventricular Assist Devices (VAD)

November 2, 2022 — For decades, left ventricular-assist devices (LVADs) have extended the lives of people whose hearts ...

Home November 02, 2022
Home
News | Ventricular Assist Devices (VAD)

October 18, 2022 — The U.S. Food and Drug Administration (FDA) is providing updates to the FDA website to include ...

Home October 18, 2022
Home
News | Ventricular Assist Devices (VAD)

August 25, 2022 — The U.S. Food and Drug Administration (FDA) issued a statement that Medtronic, Inc. is recalling ...

Home August 25, 2022
Home
News | Ventricular Assist Devices (VAD)

August 5, 2022 — Black people and women with severe heart failure who might be good candidates for surgery to implant a ...

Home August 05, 2022
Home
News | Ventricular Assist Devices (VAD)

June 23, 2022 — Medtronic, Inc. is recalling a single lot of HeartWare HVAD System batteries due to welding defects that ...

Home June 23, 2022
Home
News | Ventricular Assist Devices (VAD)

June 8, 2022 — The U.S. Food and Drug Administration (FDA) has issued a release stating that Medtronic is recalling the ...

Home June 08, 2022
Home
Subscribe Now